Emerging Atopic Dermatitis Treatments:

Slides:



Advertisements
Similar presentations
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Advertisements

Moderate-to-Severe Asthma Management
Systemic Lupus Erythematosus
Clinical Trials in IBD.
Psoriatic Arthritis.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
T-Cell Exhaustion: Can We Overcome It in Cancer?
Advances in Managing Inhibitors in Patients With Hemophilia A
Essential Updates in Atopic Dermatitis:
Clinical Developments in Inflammatory Arthritis 2017
Updates on Emerging GLP-1 Receptor Agonists
Progression After Cancer Immunotherapy in Advanced NSCLC
From Conference to Practice: Big Data in Psoriasis
Improving Acne Outcomes
Atopic Dermatitis Treatment Landscape
Updates in Management of Atopic Dermatitis From Real Patient Cases
Atopic Dermatitis Treatment Landscape
Program Goals. Program Goals What is Atopic Dermatitis?
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Chronic Idiopathic Urticaria
Addressing Disease Burden in Asthma
Expert Tips for Tackling Atopic Dermatitis in Pediatric Practice
Asthma and Atopic Comorbidities
Optimizing Management of Advanced Bladder Cancer
Translating Atopic Dermatitis
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Next-Gen Psoriasis Therapies:
Hyperhidrosis Is Burdensome!
Gene Therapy: Past, Present, and Future
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
Tackling Atopic Dermatitis
Ask the Experts.
Immunotherapy for cSCC
The JAK-STAT Pathway and Graft-vs-Host Disease
Perspectives on the Impact of Inflammation in OA
New Recommendations on How to Stage Hidradenitis Suppurativa
New Data on Emerging Treatments for Psoriasis
When Is Biologic Therapy Appropriate for HS?
The Evolving Treatment Landscape in Atopic Dermatitis
Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Parkinson Disease Psychosis
Advances in Rheumatoid Arthritis Management
Immune Checkpoint Inhibitors in Lung Cancer
Understanding and Addressing the Needs of Patients With AD
Advances in Severe Asthma Management
Guide to Atopic Dermatitis
Atopic Dermatitis in the Pediatric Practice
Expanding the Horizons in Hereditary Angioedema
EGPA.
Patient Questions and Expert Answers in Psoriasis:
Optimizing Joint Health in Hemophilia
Update on the Management of Atopic Dermatitis
Novel Concepts in the Management of RCC
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
From Adjuvant to Metastatic in Melanoma
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Pathophysiologic Targets of Allergic Asthma
Behçet Syndrome (BS) Overview
Immune Checkpoint Inhibitors in Lung Cancer
Meet the JAKs.
You Don't Know JAK in IBD.
Presentation transcript:

Emerging Atopic Dermatitis Treatments:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Atopic Dermatitis

Hypotheses of Atopic Dermatitis

Atopic Dermatitis and Immune Dysfunction

Skin Barrier Dysfunction

Immune System Dysfunction

Crisaborole Topical PDE4 Inhibitor

Crisaborole Topical PDE4 Inhibitor (cont)

Patient Education

Apremilast Oral PDE4 Inhibitor

Dupilumab IL-4 Receptor α Inhibitor

Dupilumab IL-4/IL-13 Inhibitor

Dupilumab IL-4/IL-13 Inhibitor

Dupilumab Pediatric Studies

IL-13 Inhibitors Lebrikizumab and Tralokinumab

Lebrikizumab and Tralokinumab

Nemolizumab IL-31 Receptor Inhibitor

Nemolizumab

JAK Inhibitors Baricitinib and Tofacitinib

JAK Inhibitors

Patient-Centric Management of AD

The AD Tool Kit

Concluding Remarks

Abbreviations